Paul Hastings Advising Ardea Biosciences in its $1.26B All-Cash Acquisition by AstraZeneca

April 23, 2012

San Diego, CA (April 23, 2012)- Paul Hastings LLP, a leading global law firm, announced today that the firm is representing Ardea Biosciences, a San Diego, CA-based biotechnology company, in its $1.26 billion all-cash acquisition by AstraZeneca, a global integrated biopharmaceutical company based in the United Kingdom.

Ardea is focused on the development of small-molecule therapeutics for the treatment of serious diseases. Ardeas clinically most advanced product candidate, lesinurad, is currently in Phase III development as a potential treatment for the chronic management of hyperuricaemia in patients with gout.

Global M&A chair and partner Carl Sanchez led the Paul Hastings team, which also included Antitrust partner Scott Hataway, Tax partner Alexander Lee, senior associates Claudia Simon and Elizabeth Razzano and associates Todd Schneider, Laura McGurty and Kevin Reyes.

Paul Hastings LLP is a leading global law firm with offices in Asia, Europe, and the United States. We provide innovative legal solutions to financial institutions and Fortune 500 companies. Please visit www.paulhastings.com for more information.